Bedell Frazier Investment Counseling LLC Raises Holdings in Johnson & Johnson (NYSE:JNJ)

Bedell Frazier Investment Counseling LLC raised its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.3% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 79,457 shares of the company’s stock after buying an additional 220 shares during the quarter. Johnson & Johnson accounts for about 3.7% of Bedell Frazier Investment Counseling LLC’s investment portfolio, making the stock its 6th largest position. Bedell Frazier Investment Counseling LLC’s holdings in Johnson & Johnson were worth $14,036,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Scotia Capital Inc. boosted its stake in Johnson & Johnson by 1.6% in the 4th quarter. Scotia Capital Inc. now owns 1,105,147 shares of the company’s stock valued at $195,247,000 after buying an additional 17,440 shares in the last quarter. Ieq Capital LLC boosted its stake in Johnson & Johnson by 5.1% in the 3rd quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock valued at $20,912,000 after buying an additional 6,154 shares in the last quarter. Duality Advisers LP acquired a new stake in Johnson & Johnson in the 4th quarter valued at $4,342,000. Modera Wealth Management LLC boosted its stake in Johnson & Johnson by 18.0% in the 4th quarter. Modera Wealth Management LLC now owns 44,189 shares of the company’s stock valued at $7,806,000 after buying an additional 6,738 shares in the last quarter. Finally, RFG Advisory LLC boosted its stake in Johnson & Johnson by 2.7% in the 3rd quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock valued at $3,900,000 after buying an additional 594 shares in the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.

Johnson & Johnson Stock Up 0.3 %

JNJ stock opened at $158.91 on Monday. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.07 and a quick ratio of 0.85. The stock has a market capitalization of $412.96 billion, a P/E ratio of 33.24, a P/E/G ratio of 2.71 and a beta of 0.53. The business has a 50-day moving average of $159.70 and a 200-day moving average of $166.20. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $183.35.

Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, topping the consensus estimate of $2.51 by $0.17. The company had revenue of $24.75 billion during the quarter, compared to analysts’ expectations of $23.61 billion. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. Johnson & Johnson’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.67 earnings per share. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.66 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be issued a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a yield of 3.00%. The ex-dividend date of this dividend is Monday, May 22nd. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s dividend payout ratio is presently 94.56%.

Analyst Ratings Changes

JNJ has been the subject of several research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 1st. Morgan Stanley lifted their price objective on Johnson & Johnson from $179.00 to $183.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 19th. Raymond James cut their price objective on Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a research report on Wednesday, April 19th. Piper Sandler cut their price objective on Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. Finally, Credit Suisse Group boosted their target price on Johnson & Johnson from $168.00 to $170.00 in a research report on Friday, May 5th. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $173.00.

Insider Buying and Selling

In related news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the sale, the insider now owns 9,215 shares in the company, valued at $1,425,191.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.20% of the stock is currently owned by corporate insiders.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.